COLORADO SPRINGS, Colo., July 31, 2014 /PRNewswire/ – Cannabis Science, Inc. (otc-qb:CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting, is pleased to announce that it has commenced production of multiple strains of cannabis and European Union certified hemp varieties to initiate scientific research to select the best strains for development of proprietary formulations for clinical drug development to bring the cannabis formulations to market for critical ailments such as cancer and neurological disorders.
Mr. Mario S. Lap, Director and President of European Operations, stated, “Cannabis Science intends to leverage its team’s expertise to create a framework for research and clinical testing. We are excited to report further development and progress as we proceed forward.”
The facilities are located in the Alicante region of Spain, and the Company is working with a local partner to initiate an agricultural program, to prepare GMP production and to start building the research framework to conduct scientific testing of extracts and the active constituents contained in the cannabis plant with the objective of developing selected formulations for clinical use.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as “anticipate,” “seek,” intend,” “believe,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Cannabis Science, Inc.
Dr. Dorothy Bray, CEO & Director
www.cannabisscience.com
dorothy.bray@cannabisscience.com
info@cannabisscience.com
Tel: 1.888.777.0658
Investment Inquiries
Robert Kane, CFO & Director
robert.kane@cannabisscience.com
Tel: 1.561.420.4824
Raymond C. Dabney, Management Consultant, Co-Founder
raymond@cannabisscience.com
Tel: 1.310.650.3788
SOURCE Cannabis Science, Inc.
Copyright (C) 2014 PR Newswire. All rights reserved
Additionally, potential medicinal applications are being investigated using strains of European ...
No comments:
Post a Comment